多瑞医药
(301075)
| 流通市值：23.13亿 | | | 总市值：23.13亿 |
| 流通股本：8000.00万 | | | 总股本：8000.00万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 49,443,387.5 | 240,628,115.62 | 200,520,158.82 | 150,380,490.51 |
| 营业收入 | 49,443,387.5 | 240,628,115.62 | 200,520,158.82 | 150,380,490.51 |
| 二、营业总成本 | 74,258,315.38 | 315,957,682.01 | 233,238,610.81 | 162,260,202.56 |
| 营业成本 | 41,173,602.76 | 138,565,119.17 | 118,802,890.86 | 91,836,317.76 |
| 税金及附加 | 1,004,871.11 | 2,120,122.6 | 1,427,645.97 | 1,051,236.71 |
| 销售费用 | 10,521,016.71 | 80,880,724.88 | 63,176,797.95 | 42,980,480.94 |
| 管理费用 | 11,790,524.92 | 54,164,144.37 | 31,152,149.87 | 19,778,014.62 |
| 研发费用 | 5,832,477.61 | 37,004,150.51 | 17,986,703.87 | 6,413,461.72 |
| 财务费用 | 3,935,822.27 | 3,223,420.48 | 692,422.29 | 200,690.81 |
| 其中:利息费用 | 4,201,164.89 | 7,900,196.15 | 4,272,293.15 | 2,766,501.51 |
| 其中:利息收入 | 280,793.1 | 4,740,791.72 | 3,678,758.22 | 2,650,942.4 |
| 加:公允价值变动收益 | -54,425.55 | 541,833.33 | 531,891.89 | 251,984.94 |
| 加:投资收益 | 1,062,155.27 | 5,331,242.09 | 6,153,254.01 | 3,929,896.88 |
| 资产处置收益 | 9,561.89 | 43,526.49 | 22,631.75 | -22,651.26 |
| 资产减值损失(新) | -266,616.2 | -10,492,399 | 455,047.8 | 499,141.88 |
| 信用减值损失(新) | -1,053,138.23 | -7,318,184.14 | -405,561.8 | 257,982.45 |
| 其他收益 | 2,383,088.88 | 1,460,375.37 | 231,056.25 | 109,396.68 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -22,734,301.82 | -85,763,172.25 | -25,730,132.09 | -6,853,960.48 |
| 加:营业外收入 | - | 580,164.91 | 51,155.77 | 322,162.34 |
| 减:营业外支出 | 113,355.07 | 588,342.12 | 503,844.43 | 107,399.44 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -22,847,656.89 | -85,771,349.46 | -26,182,820.75 | -6,639,197.58 |
| 减:所得税费用 | -131,531.01 | -746,158.76 | 375,516.07 | 1,155,436.26 |
| 六、净利润 | -22,716,125.88 | -85,025,190.7 | -26,558,336.82 | -7,794,633.84 |
| 持续经营净利润 | -22,716,125.88 | -85,025,190.7 | -26,558,336.82 | -7,794,633.84 |
| 归属于母公司股东的净利润 | -15,598,165.78 | -62,666,665.21 | -17,078,738.2 | -3,276,411.4 |
| 少数股东损益 | -7,117,960.1 | -22,358,525.49 | -9,479,598.62 | -4,518,222.44 |
| (一)基本每股收益 | -0.2 | -0.79 | -0.21 | -0.04 |
| (二)稀释每股收益 | -0.2 | -0.79 | -0.21 | -0.04 |
| 八、其他综合收益 | - | 461,177.5 | - | - |
| 归属于母公司股东的其他综合收益 | - | 461,177.5 | - | - |
| 九、综合收益总额 | -22,716,125.88 | -84,564,013.2 | -26,558,336.82 | -7,794,633.84 |
| 归属于母公司股东的综合收益总额 | -15,598,165.78 | -62,205,487.71 | -17,078,738.2 | -3,276,411.4 |
| 归属于少数股东的综合收益总额 | -7,117,960.1 | -22,358,525.49 | -9,479,598.62 | -4,518,222.44 |
| 公告日期 | 2025-04-25 | 2025-04-18 | 2024-10-25 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |